Adult neurogenesis persists in the subventricular zone and is decreased in Parkinson disease (PD). The therapeutic potential of neurogenesis in PD requires understanding of mechanisms of 1) neural stem cell generation; 2) their guidance to the lesion site; and 3) the environment that enables neuronal differentiation, survival, and functional integration. We examined the combined intraventricular infusion of epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF-2) in a 6-hydroxydopamine-induced rodent model of PD. Epidermal growth factor and FGF-2 induced a massive increase in cell proliferation and in numbers of doublecortinexpressing neuroblasts in the subventricular zone. These growth factors also increased dopaminergic neurogenesis in the olfactory bulb and promoted the migration of newly generated neuroblasts from the subventricular zone into the adjacent striatum. The effects of EGF and FGF-2 were present in unlesioned animals but were dramatically enhanced in 6-hydroxydopamine-lesioned animals.
INTRODUCTION
Neurogenesis persists into adulthood in 2 brain regions: the hippocampus and the subventricular zone (SVZ) (1) . In the rodent, more than 30,000 neuroblasts per day exit the SVZ for the rostral migratory stream (2) and migrate toward the olfactory bulb (3) , where the surviving neuroblasts differentiate and integrate as new olfactory interneurons (4, 5) . Adult neurogenesis is modulated in animal models of Parkinson disease (PD), including >-synuclein transgenic mice and acute dopaminergic lesion models (6Y8). Olfactory deficits represent some of the early symptoms in PD (9) , and an increased number of dopaminergic neurons is observed in the olfactory bulbs of PD patients (10) . Similarly, we demonstrated increased olfactory dopaminergic neurogenesis in a PD animal model (7) . Moreover, the rate of proliferation and/or survival of newly generated cells in neurogenic regions is decreased in PD (11) and in >-synuclein transgenic mice (6, 8) .
Recent studies indicate that adult neural precursor cells may be recruited from neurogenic regions to migrate toward lesion sites. For example, newly generated neural stem cells migrate from the SVZ into the ischemic striatum and express markers of developing and mature striatal spiny neurons (12) . Interestingly, after global ischemia, recruitment of new hippocampal pyramidal neurons is facilitated by intraventricular infusion of epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2) (13). These results indicate that neurogenesis responses to acute lesions can be modulated through the application of exogenous factors.
Epidermal growth factor and FGF-2 are potent factors that increase the proliferation and mediate long-term survival of SVZ-derived progenitor cells (14) . Intraventricular infusion of FGF-2, but most strikingly EGF, induced massive proliferation in the SVZ (15, 16) . Furthermore, EGF, but not FGF-2, redirected newly generated cells to the adjacent striatum (16) . Epidermal growth factor enhanced glial fate determination, whereas FGF-2 increased olfactory bulb neurogenesis in naive animals. Epidermal growth factor also proved effective in increasing striatal migration of newly generated neurons toward the ischemic striatum (17, 18) .
In this study, we explored the growth factor-based strategy of a combined infusion of EGF and FGF-2 to redirect newly generated cells into a dopamine-depleted striatum. The analysis focused on proliferation, migration, differentiation, and survival of newly generated cells in 2 regions, the olfactory bulb (the physiologic target region for newly generated SVZ-derived cells) and the dopaminedepleted striatum.
MATERIALS AND METHODS

Animals
Three-month-old female Wistar rats (n = 64; Charles River Laboratories, Sulzfeld, Germany; weight, 220Y250 g) were randomly divided into 8 groups (n = 8). Groups were defined by lesion type (6-hydroxydopamine or ascorbic acid control lesion [AA] ) and treatment (EGF/FGF-2 or artificial cerebrospinal fluid [aCSF] ) and by the time point of perfusion, either after 2 weeks (time point 1) or 6 weeks (time point 2, experimental groups; Fig. 1A , B, D). All experiments were performed in accordance with the European Communities Council Directive of November 24, 1986 (86/609/EEC) and approved by the local governmental commission for animal health.
Nigrostriatal Lesions
Unilateral elimination of the dopamine-containing neurons in the substantia nigra pars compacta was achieved by stereotactic injection of 2 doses of 2 Kl of 6-OHDA (Sigma, St Louis, MO), 5 Kg/Kl in isotonic sodium chloride solution with 0.02% AA, or 0.02% AA alone in the right medial forebrain bundle (MFB; (7)).
Osmotic Minipump Implantation
Eight days after the 6-OHDA lesions, cannulas were implanted into the lateral ventricle (16) and connected to an osmotic minipump (Alzet 2002; Alza, Palo Alto, CA; Fig.  1C ). Human recombinant EGF (1 Kg/Kl; Relia Tech GmbH, Braunschweig, Germany) and FGF-2 (1 Kg/Kl; Relia Tech) were delivered at 0.5 Kl/h, resulting in 720 ng/d of EGF and FGF-2 for 7 days. This amount of growth factors was chosen to deliver a similar total dose as used in previous studies: 1,440 ng/d for 3 days after global ischemia (13) and 360 ng/d for 14 days in naive animals (16) . Starting 8 days after the 6-OHDA lesions, the rats received injections of bromodeoxyuridine (BrdU; 50 mg/kg, i.p.; Sigma) twice daily for 8 consecutive days. After 6-OHDA injections into the MFB, dopaminergic neurons degenerated within 12 hours, and striatal dopamine levels are permanently depleted 2 to 4 days later (20, 21) . Thus, based on this lesion paradigm, dopaminergic neurons would have degenerated before the first injection with BrdU was applied in this model. The animals were perfused using 4% buffered paraformaldehyde (7) . The olfactory bulbs were transected anterior to the septum and cut sagittally in 20-Km sections, and the remaining hemispheres of the brains were cut frontally into 40-Km sections. FIGURE 1. Experimental design. At time points 1 (A) and 2 (B), the groups (n = 8 rats/group) were generated in a crossover design depicted in (C). Lesions were performed at the following coordinates from the bregma line: anteroposterior, j4.3 mm; mediolateral, j1.5 mm; and dorsoventral, j7.8 and j7.5 mm. The implanted cannula was located at anteroposterior, 0.0 mm; mediolateral; j1.2 mm; dorsoventral, 5 mm from the bregma line. (D) Panel shows the frontal section according to Paxinos and Watson (19) , with the tyrosine hydroxylase-deprived striatum on the right side. The image shows the SVZ, the LV, the STRI, the CC, and the injection site of the cannula attached to the osmotic minipump. Two areas, (A) (medial) and (B) (lateral), within the striatum were defined as 2 adjacent rectangular areas of 250 Â 500 Km in size, the medial border 100 Km distant from the SVZ. 6-OHDA, 6-hydroxydopamine; AA, ascorbic acid; aCSF, artificial cerebrospinal fluid; CC, corpus callosum; EGF-FGF-2, epidermal growth factor and fibroblast growth factor-2; STRI, striatum; SVZ, subventricular zone. Original drawing based on figure in (19) .
Immunohistochemistry and Immunofluorescence
Immunohistochemistry and triple-labeling immunofluorescence for free-floating sections were performed with the following primary antibodies: BrdU, rat monoclonal (1:500; Oxford Biotechnology, Oxford, UK); glial fibrillary acidic protein (GFAP), rabbit polyclonal (1:1000; Dako, Hamburg, Germany); neuronal nuclei (NeuN), mouse monoclonal (1:500); tyrosine hydroxylase (TH) rabbit monoclonal (1:1000; both Chemicon, Temecula, CA); doublecortin (DCX) goat polyclonal (1:500); and proliferating cell nuclear antigen (PCNA) mouse monoclonal (1:1000; both Santa Cruz Biotechnology, Santa Cruz, CA). Sections were stained with the following secondary antibodies: donkey >-goat, mouse, rabbit, or rat conjugated with fluorescein isothiocyanate, rhodamine X, Cy5, or biotin (1:500; Jackson Immuno Research, West Grove, PA). For immunohistochemistry, sections were stained with donkey >-mouse biotinylated, donkey >-rabbit biotinylated, or donkey >-goat biotinylated antibodies (1:500; Jackson Immuno Research), followed by the avidin-biotin-peroxidase complex (1:100; Vectastain Elite, Vector Laboratories, Burlingame, CA). For immunofluorescence, the following secondary antibodies were used: rhodamine X-tagged donkey >-mouse and donkey >-rabbit, or fluorescein isothiocyanateYtagged donkey >-rat or donkey >-goat, or Cy-5-labeled donkey >-rabbit. For detection of BrdU-or PCNA-labeled nuclei, DNA denaturation steps with formamide and HCl preceded the incubation with antibodies against BrdU or PCNA (4, 6).
Terminal Deoxynucleotidyl Transferase Deoxyuridine Triphosphate Nick End Labeling
Cell death was detected using an Apoptag in situ cell death detection kit (Intergene, Purchase, NY) in a modified procedure for free-floating sections (22) .
Counting Procedures
For quantification, a systematic counting procedure was performed (23) using a semiautomatic stereology system, including the use of an optical dissector, which is a 3-dimensional probe that samples isolated particles with a uniform probability irrespective of size, shape, and orientation in the tissue. Sampling with the optical dissector was achieved with a modified Leika microscope projected onto a computer screen by a video camera (Stereoinvestigator; MicroBrightField, Colchester, VT; [24] ). Doublecortin (DCX-) and PCNA-positive cells in the SVZ were counted using a randomized systemic approach within a 20 Â 20-Km counting frame that was spaced in a 100 Â 100-Km counting grid (Tables 1, 2 ). For the olfactory bulb granule cell layer, every fourth section (160-Km interval) of the right olfactory bulb was analyzed for BrdU-positive cells within a 50 Â 50-Km counting frame that was spaced in a 500 Â 500-Km counting grid. The glomerular layer was counted exhaustively because newly generated cells are less frequent in this location.
A ventriculolateral gradient of DCX-expressing cells was present in the striatum at a lower magnification. Therefore, densities of DCX-positive cells in this region were determined by selecting predetermined fields on each section (16) . In brief, every sixth section from a coronal series was selected between the corpus callosum genu and the anterior commissure crossing. As illustrated in Figure 1D , DCX-positive cells were counted in 2 predefined adjunct rectangular areas ( Fig. 1D ; A, medially; B, laterally; size, 250 Â 500 Km each), the medial end lying at a distance of 100 Km from the lateral ventricle wall. Density is presented as the number of cells (in thousands)/cubic millimeter.
Colabeling was analyzed sequentially at each wavelength and in its z axis to ensure that the fluorophores were present in the identical focal plane as single BrdU-positive (newborn cells) and BrdU/NeuN coexpressing cells (newborn neurons), and also for the glomerular layer BrdU/NeuN/TH coexpressing cells (newborn dopaminergic neurons). Double/ triple labeling was imaged by confocal laser microscopy using a pinhole setting of 1.02 Km. On average, 100 BrdUpositive cells were analyzed in the granule cell and glomerular layers of the olfactory bulb for neuronal differentiation by using a confocal scanning laser microscope and †, Cell density of DCX-expressing neuroblasts in 2 predefined areas (A, B) of the striatum (Fig. 1D) . ‡, p G 0.05 compared with AA/aCSF. §, p G 0.05 compared with 6-OHDA/aCSF. ¶, p G 0.05 compared with AA/EGF-FGF. AA, ascorbic acid control lesion; aCSF, artificial cerebrospinal fluid; DCX, doublecortin; EGF, epidermal growth factor; FGF-2, fibroblast growth factor-2; PCNA, proliferating cell nuclear antigen; 6-OHDA, 6-hydroxydopamine; SD, standard deviation; SVZ, subventricular zone.
software (Leica TCS-NT, Bensheim, Germany). To avoid cross detection of fluorescein isothiocyanate signals in the rhodamine channel and rhodamine-X detection in the CY5 channel, the fluorescence images were recorded sequentially for each channel with only the corresponding single-wavelength laser line (488, 568, or 647 nm) activated. In the striatum, 100 BrdU-positive cells were analyzed for colabeling with TH.
Statistical Analysis
Statistical analysis was performed using a 1-way analysis of variance, followed by the Bonferroni multiple comparison test (Prism Graph Pad Software, San Diego, CA). The data are expressed as mean values T SD. The significance level was set at p G 0.05 unless otherwise indicated.
RESULTS
We studied the effects of combined administration of EGF and FGF-2 in a 6-OHDA MFB lesion model. After the induction of a dopaminergic deficit, the combination of EGF and FGF-2 was infused continuously for 1 week into the lateral ventricle adjacent to the dopamine-depleted SVZ and striatum. Infusion of aCSF was used as control. During the infusion period, BrdU was intraperitoneally injected to labeldividing cells. Animals were killed on the last day of the infusion period to study early effects of the growth factors (time point 1) or were kept for an additional 4 weeks after withdrawal of the growth factors (time point 2) to analyze the survival and differentiation of newly generated cells (Fig. 1A, B, C) .
SVZ Proliferation Is Massively Increased in EGF-/ FGF-2-Treated Dopamine-Depleted Rats
We applied 6-OHDA stereotactically into the MFB and confirmed the completeness of the dopaminergic deafferentation in each 6-OHDA-lesioned animal. All 6-OHDA-lesioned animals had a virtually complete loss of ipsilateral striatal TH-immunoreactive fibers. Subventricular zone proliferation was assessed by immunolabeling sections with PCNA, a marker of proliferating cells (25) . The presence of the PCNA antigen reflects the dividing SVZ population at the time of perfusion, and this method guarantees that newly generated cells that are several days of age are not included in the measurement. In agreement with our recent study (7), a significant decrease in the number of PCNA-labeled nuclei was detected in the SVZ of the 6-OHDA/aCSF group compared with the AA/aCSF group (58% decrease; p G 0.05; Table 1 , Fig. 2 ). The combined EGF/FGF-2 infusion synergistically increased the number of dividing cells in the SVZ. A 2.5-fold increase in SVZ proliferation was found in the AA/EGFYFGF-2 group compared with the AA/aCSF group (p G 0.001; Table 1 , Fig. 2 ). However, in contrast to EGF alone, which resulted in numerous periventricular hyperplastic nodules (16) , only a few nodules were observed in the EGF-FGF-2-treated group, and most of these were located within the lateral wall of the SVZ. Analysis of the effects of EGF-FGF-2 infusion after the 6-OHDA lesions revealed increased SVZ proliferation, and thickening of the SVZ was even more pronounced than in the AA/EGF-FGF-2 nonlesioned groups. A 5-fold increase in PCNA-expressing cells was found in the 6-OHDA/EGF-FGF-2 group compared with AA/aCSF, and a 2-fold increase was observed compared with the AA/EGF-FGF-2 group (p G 0.001). The SVZ volume in the 6-OHDA/EGF-FGF-2-treated group nearly doubled (Table 1, Fig. 2 ).
EGF-FGF-2 Substantially Increased Numbers of SVZ Neuroblasts in Dopaminergic-Lesioned Rats
Doublecortin is a protein expressed specifically and transiently in neuronal precursors and young neurons (26) . In the SVZ of the 6-OHDA/aCSF animals, the decreased cell proliferation was accompanied by a 20% decrease in the number of DCX-expressing cells (p G 0.05). The opposite effect was noted in the 6-OHDA/EGF-FGF-2 group, in which a significant increase of DCX-positive neuroblasts was detected compared with 6-OHDA-/aCSF-infused rats, and numbers of DCX-expressing cells in the SVZ showed a 5-fold increase (p G 0.001; Table 1 , Fig 3) .
Decreased Olfactory Bulb Neurogenesis in the Granule Cell Layer
The impact of combined EGF/FGF-2 infusion on the survival and differentiation of newly generated cells in the olfactory bulb was further investigated. Numbers of BrdUpositive profiles were determined, and the neuronal identity of the newly generated cells was characterized. The total numbers of newly generated BrdU/NeuN coexpressing cells (new neurons) or BrdU/TH coexpressing cells (new dopaminergic neurons) were used to evaluate changes in neurogenesis. Newly generated cells in the olfactory bulb were counted separately in the granule cell layer and the glomerular layer.
In the olfactory granule cell layer, the site of integration for most newly generated interneurons, BrdU cell numbers in the 6-OHDA/aCSF group were almost identical to the AA/ aCSF group 6 weeks after the 6-OHDA lesion (approximately 190.5 Â 10 3 BrdU-expressing cells). Similar to the AA/aCSF group, most of the BrdU-positive cells in the 6-OHDA/aCSF group became new neurons at this time point, as determined by colocalization of BrdU and NeuN (approximately 92% neuronal ratio; Table 2 , Fig. 4C, D) .
In contrast, the total number of BrdU-labeled cells in the granule cell layer was diminished in the AA/EGF-FGF-2 group, with a 42% (2 weeks) and 29% (6 weeks) reduction in BrdU-positive cells as compared with the AA/aCSF group, respectively (Table 2) . Moreover, significantly fewer new cells in this group adopted a neuronal phenotype (8.8% less compared with AA/aCSF). This implies that despite the increased proliferation in the SVZ, fewer new neurons reached the granule cell layer of the olfactory bulb, resulting in a net 35% decrease in the total number of BrdU/NeuN colabeled cells.
Similarly, fewer newly generated cells were present in the olfactory bulb granule cell layer in the 6-OHDA/ EGF-FGF-2 animals (33% reduction at 2 weeks after the lesion and 42% reduction at 6 weeks compared with the 6-OHDA/aCSF group; Table 2 ). A decrease in neuronal differentiation was also present in the 6-OHDA/EGF-FGF-2 group. In the latter group, only 83% of the BrdU-expressing cells adopted a neuronal phenotype (9% less than 6-OHDA/ aCSF). Therefore, olfactory neurogenesis in the granule cell layer of 6-OHDA/EGF-FGF-2Ytreated animals was drastically reduced to 53% of the respective control group (6-OHDA/aCSF; Table 2 , Fig. 4C, D) . Because most migrating new interneurons integrate into the granule cell layer, the total number of new neurons integrating in the olfactory bulb significantly decreased after the combined growth factor administration despite increased SVZ cell proliferation (Fig. 6B) .
Increased Neurogenesis in the Olfactory Bulb Glomerular Layer After 6-OHDA Lesioning
In the glomerular layer, there was a significant increase in the number of BrdU-positive cells in the 6-OHDA/aCSFlesioned animals compared with the AA/aCSF group (50% increase; p G 0.001; Table 2 ). More BrdU-/TH-positive cells were added to the olfactory bulb glomerular layer ipsilateral to the lesion of the 6-OHDA-injected rats compared with AA/aCSF (4-fold increase; p G 0.001; Table 2 , Fig. 4A, B ). An increase in dopaminergic neurogenesis was also observed in the AA/EGF-FGF-2 group. In the latter group, numbers of newly generated TH-expressing cells increased significantly compared with AA/aCSF at 6 weeks (p G 0.001; Table 2 , Fig. 6B ). In addition, the rate of dopaminergic differentiation increased, with 11.6% more newly generated cells adopting a dopaminergic phenotype. In the 6-OHDA/EGF-FGF-2 group, dopaminergic neurogenesis increased as well, and a 3-fold increase of the net dopaminergic neurogenesis could be measured (p G 0.001). It is important to note that both the dopaminergic lesion and EGF-FGF-2 infusion independently induced an increase in dopaminergic neurogenesis in the glomerular layer of the olfactory bulb. However, there was no additive effect of both stimuli ( Table 2) .
Neuroblast Migration to the Dopamine-Depleted Striatum
Next, we studied where the super numerous newly generated cells of the SVZ migrate. We recently reported that the transient expression pattern of DCX in neuronal precursors could be used to quantify modulations in neurogenesis levels (27, 28) . In the growth factorYtreated groups, an increased number of DCX-expressing cells was noted in the lesioned striatum adjacent to the SVZ (Fig. 3 ) and, to a lower extent, also in the corpus callosum and lateral septum.
In the striatum, most DCX-expressing cells were found in the medial part, adjacent to the SVZ (Fig. 3C) , whereas NeuN red) show the cell indicated by inset and arrow in (A) and (C) in xy and yz reconstructions. Scale bar = 25 Km. Epidermal growth factor and fibroblast growth factor-2 induced the generation of doublecortin (DCX)-positive neuroblasts in the striatum of 6-hydroxydopamine (6-OHDA)-lesioned animals (E-G). Numerous BrdU-positive cells (E, green) are present within the adjacent striatum at the end of the growth factor infusion (time point 1) in 6-OHDA/lesioned animals. However, only a few cases show colabeling with DCX (red in E, G). Xyz reconstruction and color separation of a confocal image depicting colabeling (E, white arrow) of a cell double labeled for BrdU (green; F, white arrow in xz reconstruction) and DCX (red, G: white arrow in yz reconstruction). Scale bars = (E-G) 25 Km. Optical thickness was 2 Km or less.
only a few DCX-expressing neuroblasts could be found in the regions greater than 600 Km away from the lateral aspect of the SVZ. Moreover, a radial gradient of DCXexpressing cells was noted, suggesting migration of SVZderived cells into the neighboring striatum. In contrast to the observation made in ischemia-damaged striatum, the striatal DCX-expressing cells detected in this study did not migrate in chains (12) but were rather observed as single cells dispersed within the striatum. The morphologies of the striatal DCX-expressing cells (Fig. 3DYF ) differed from those in the SVZ-olfactory bulb or hippocampus (Fig. 3G) . In neurogenic regions, DCX neuroblasts had fusiform somata with elongated processes consistent with a migratory stage. In contrast, only few striatal DCX-expressing neuroblasts resembled this phenotype. The striatal DCX-expressing cells had fewer short processes extending in different directions (Fig. 3CYF) . Next, we quantified the numbers of DCXexpressing neuroblasts in the striatum. Areas adjacent to the SVZ were chosen because the DCX-expressing cells were observed in a ventriculolateral gradient, and the low number of DCX-expressing cells present in the most lateral aspect of the striatum would not allow a reliable analysis. Two areas were chosen (area A, 100 Km away from the lateral end of the SVZ; area B, 350 Km away from the lateral end of the SVZ; 250 Â 500 Km 2 each).
No significant difference in DCX-positive cell numbers was found in the striatum between the 6-OHDA/aCSF-and the AA-/aCSF-treated group (Table 1) . However, growth factor infusion significantly increased numbers of DCX-expressing neuroblasts within the analyzed areas. The growth factorY associated increase was further enhanced after dopaminergic lesions, as detected in the 6-OHDA/EGF-FGF-2-treated rats. 6-hydroxydopamine/EGF-FGF-2-treated animals showed 9-to 20-fold increases in DCX-expressing neuroblasts than AA/ aCSF in the areas 100 Km (area A; p G 0.001) and 350 Km (area B; p G 0.001) distant from the lateral border of the SVZ, respectively ( Table 1, Fig. 6A, C) .
Phenotypes of DCX-Positive Neuroblasts and Newly Generated Cells in the Striatum
The phenotypes of DCX-positive cells in the striatum adjacent to the SVZ were analyzed by immunofluorescence (Fig. 4G) . Although DCX-positive cells in the rostral migratory stream showed frequent incorporation of BrdU, those located in the striatum rarely displayed BrdU incorporation (Fig. 4G) . We therefore further studied BrdU incorporation in the striatum. Most of the BrdU-positive cells were in the medial part of the striatum with a ventriculolateral gradient. We searched for neurogenesis in this area, but no double labeled BrdU and NeuN cells could be detected in the striatum of any treatment group. We further examined the striatum for the presence of colabeling of BrdU and TH and also found that no TH/BrdU coexpressing cells were detected in the striatum of 6-OHDA-lesioned rats. Because a large number of GFAP-positive cells were observed in the medial striatum (Fig. 5A) , we studied coexpression of GFAP with BrdU. Many BrdU-positive cells were double labeled with GFAP (Fig. 5AYD ), indicating that a large fraction of the newly generated cells acquired a glial phenotype 4 weeks after growth factor infusion in the lesioned striatum, resulting in a pronounced gliogenesis. In addition, we performed terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) analysis to investigate cell death in the striatum. However, very few TUNEL-positive profiles could be found in the striatum regardless of the treatment groups, suggesting that cell death remained an infrequent event in the striatum regardless of the treatment group. , and olfactory bulb as well as the striatum. 6-hydroxydopamine lesions (BII) result in increased dopaminergic neurogenesis in the glomerular layer of the olfactory bulb (blue arrows). Infusion of EGF/FGF-2 without a 6-OHDA lesion (BIV) leads to decreased rostral migration to the olfactory bulb (thin red arrow), concomitant with a proportional increase in dopaminergic neurogenesis within the glomerular layer of the olfactory bulb (blue arrows) and enhanced migration of neuroblasts towards the striatum (green arrows). Infusion of EGF/FGF-2 in 6-OHDA-lesioned animals (BV) also leads to decreased rostral migration to the olfactory bulb (thin red arrow) with a proportional increase in dopaminergic neurogenesis within the glomerular layer of the olfactory bulb (blue arrows). However, it is important to note that the migration of neuroblasts after growth factor infusion is exaggerated in the dopamine-depleted striatum (green arrows). AA, ascorbic acid control lesion; aCSF, artificial cerebrospinal fluid. Original drawing based on figure in (19) .
DISCUSSION
We report here that a combined EGF and FGF-2 infusion resulted in increased cell proliferation in the SVZ. This increase was even more pronounced in animals with a dopaminergic deficit. Paradoxically, a decrease in neurogenesis was detected in the olfactory bulb granule cell layer, the region in which most SVZ-derived interneurons physiologically integrate. In contrast, in the olfactory bulb glomerular layer, an increase in dopaminergic neurogenesis was observed independently after dopaminergic lesioning and growth factor application, but without resulting in an additive effect. The net decrease in the number of newly generated neurons reaching the olfactory bulb may be explained by the redirection of a fraction of the SVZ-derived cells toward the adjacent striatum (Fig. 6) . Even if several of these cells migrating toward the striatum were neuroblasts, as revealed by their expression of DCX, there was no evidence of newly generated mature neurons in the striatum. Most of the newly generated cells showed a glial phenotype.
Because dividing cells are rare in the substantia nigra (29, 30), we were particularly interested in studying the induction of neuroblast migration from the SVZ toward the dopamine-depleted striatum for cellular replacement in this region. Striatal cell replacement therapies in PD have been the target of numerous transplantation approaches (31) because direct release of dopamine from grafted cells is considered to be an effective therapy for relieving motor symptoms in PD patients (32) . Because we observed a ventriculolateral gradient, we hypothesize that the striatal DCX-expressing neuroblasts were derived from the SVZ. The rare occurrence of SVZ hyperplastic nodules of the growth factor-treated animals seems to further demonstrate that newly generated cells were able to exit the SVZ. Alternatively, the DCX-expressing neuroblasts can arise locally from neural progenitors residing within the striatum. It is important to note that only a few DCX-positive cells colabel with BrdU. Low rates of BrdU-positive neuroblasts within the striatum have also been described in Huntington disease and stroke models (17, 33) .
Transit-amplifying type C cells constitute most EGF receptor-expressing cells in the SVZ and therefore form the EGF-responsive progenitor population in the adult brain (33) . Increased proliferation after EGF infusion has been attributed to EGF responsiveness of SVZ type C cells and, in addition, exposure to high doses of EGF results in the conversion of C cells from a F-aminobutyric acid (GABA)ergic neuronal lineage precursor into a highly migratory and proliferative glial component (34) . Thus, the increased striatal gliogenesis detected in this study is in agreement with previously reported observations. In addition, ectopic grafting in the striatum of SVZ-derived neuronal committed interneurons revealed that neuronal precursors can undergo glial differentiation outside their physiologic environment (35) .
The extent of hyperplastic nodules induced by EGF was less pronounced in the present study than in previous ones, most likely because the newly generated cells in the combined presence of EGF and FGF-2 are able to transform from the transit-amplifying type C cell toward a migratory neuroblast. The increase in DCX-expressing neuroblasts in the growth factorYtreated animals bearing a dopaminergic deficit indicates that the dopamine-depleted striatum further attracts neuroblast migration from the SVZ. Complimentary factors are necessary to support a final neuronal maturation in the striatum.
In 6-OHDA lesion models, the striatal infusion of the EGF-receptor ligand transforming growth factor-> induced a dramatic proliferation and redirected the migration of newly generated SVZ-derived cells toward the dopamine-depleted striatum (36, 37) . However, the previously described generation of new dopaminergic neurons within the striatum (36) could not be confirmed, nor could the generation of new neurons or neuroblasts be detected (37) . Other factors such as platelet-derived growth factor and brain-derived neurotrophic factor may also be able to support the generation of neuronal cells in the striatum (38) . However, these factors do not promote dopaminergic differentiation. Differential effects of recruitment of newly generated neurons have been demonstrated in stroke models. Here, neuronal replacement originating from endogenous SVZ precursors has been demonstrated after transient middle cerebral artery occlusion in adult rodents (12) . Interestingly, this effect of attracting SVZ precursors to the striatum is long-lasting and is present in aged rodents and in humans after ischemia (39, 40) .
Recent studies showed that dopamine depletion reduces cell proliferation in the SVZ (7, 11, 41) . This was paralleled by findings observed in the SVZ of patients with PD (11) . Recently, using retrograde labeling, it became evident that dopaminergic substantia nigra neurons project toward the SVZ, suggesting a potential role of dopaminergic innervation in this neurogenic region (42) . Interestingly, in PD patients' brains and in 6-OHDA-lesioned rats, a decrease in the protein content of EGF was detected in the prefrontal cortex and striatum. Moreover, the expression of the EGF receptors ErbB1 and ErbB2 was downregulated in prefrontal cortex and striatum in PD (43) . This indicates that EGF levels are reduced in PD patients and point toward the potential therapeutic efficacy of EGF-based induction of the generation of endogenous neural progenitors in the adult human brain.
In patients with PD, and in asymptomatic patients who subsequently developed clinical parkinsonism (9), olfactory dysfunction precedes motor symptoms (44, 45) . Interestingly, neuropathologic examinations of the olfactory bulb in PD brains have revealed >-synuclein-immunopositive Lewy bodies and Lewy neurites in the olfactory bulb at very early stages of the disease (46) , as well as a significant increase in TH-positive cells in the olfactory bulb glomerular layer (10) . Given the fact that there is continuous integration of olfactory interneurons, this can potentially link a disturbed adult neurogenesis to the PD-related olfactory dysfunction.
Considering the continuous generation of olfactory interneurons and the capacity of the adult brain to respond to growth factor-associated signals, our data point toward a mean to repopulate the dopamine-depleted striatum with neuroblasts. In contrast to the olfactory bulb, however, the striatum lacks microenvironmental cues to: 1) induce a mature dopaminergic phenotype and 2) to integrate these cells in striatal circuitries. Hence, after identifying some of the mechanisms recruiting cells suited for striatal regenerative strategies in a PD model, further efforts are needed to direct these super numerous cells toward a dopaminergic fate. Moreover, because synucleinopathies have been recognized as not being limited to dopaminergic neuron cell populations (46), our findings have general relevance to understanding mechanisms of cell migration in diseased regions of the brain.
